The coxibs and traditional nonsteroidal anti-inflammatory drugs: A current perspective on cardiovascular risks

Canadian Journal of Cardiology

Volumn 23, Issue 2, 2007, Pages 125-131

  Cairns, John A ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b GLD Health Care Centre   (Canada)

Author keywords

Clinical trials; Complications; Drugs; Epidemiology; Myocardial infarction; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; GLUCOCORTICOID; IBUPROFEN; INDOMETACIN; LANSOPRAZOLE; LUMIRACOXIB; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; PARECOXIB; PLACEBO; PROSTANOID; PROTON PUMP INHIBITOR; ROFECOXIB; STEROID; VALDECOXIB; WARFARIN;

ANGINA PECTORIS; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIGESTIVE SYSTEM ULCER; DRUG LABELING; DRUG MARKETING; DRUG MEGADOSE; DRUG USE; GASTROINTESTINAL SYMPTOM; HEART DEATH; HEART FAILURE; HEART INFARCTION; HUMAN; LOW DRUG DOSE; MONOTHERAPY; PATIENT COMPLIANCE; REVIEW; STROKE; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; CHEMICALLY INDUCED DISORDER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; HUMANS;

EID: 34047120219     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(07)70732-8     Document Type: Article

References (41)

1. Bombardier C. An evidence-based evaluation of the gastrointestinal safety of coxibs. Am J Cardiol 2002;89:3D-9D.
2. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J Clin Invest 2006;116:4-15.
3. Waxman HA. The lessons of Vioxx - drug safety and sales. N Engl J Med 2005;352:2576-8.
4. Dai C, Stafford RS, Alexander GC. National trends in cyclooxygenase-2 inhibitor use since market release: Nonselective diffusion of a selectively cost-effective innovation. Arch Intern Med 2005;165:171-7.
5. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
6. Bresalier RS, Sandler RS, Quan H, et al.; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102. (Erratum in 2006;355:221).
7. Solomon SD, McMurray JJ, Pfeffer MA, et al; Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
8. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-91.
9. Jenkins JK, Seligman PJ. FDA Memorandum. Analysis and recommendations for Agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk. 〈www.fda.gov/ohrms/dockets/ac/O6/briefing/ 2006.4202B1_09_FDA-Tab09.pdf〉 (Version current at November 30, 2006).
10. Health Canada. Report of the Expert Advisory Panel on the Safety of Cox-2 Selective Non-steroidal Anti-inflammatory Drugs (NSAIDs). 〈www.hc-sc.gc.ca/dhp-mps/prodpharma/activit/sci-consult/cox2/ sap_report_gcs_rapport_cox2_e.html〉 (Version current at November 30, 2006).
11. Health Canada Guidance for Industry. 〈www.hc-sc.gc.ca/dhp-mps/ alt_formats/hpfb-dgpsa/pdf/prodpharma/nsaids_ains_e.pdf〉 (Version current at January 16, 2007).
12. European Medicines Agency. Press Release: European Medicines Agency concludes action on COX-2 inhibitors. 〈www.emea.eu.int/ Cox2inhibitors.htm〉 (Version current at i January 24, 2007).
13. Mitchell JA, Warner TD. COX isoforms in the cardiovascular system: Understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov 2006;5:75-86.
14. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42.
15. Patrono C, Coller B, FitzGerald GA, Hirsh J. Roth G. Platelet-active drugs: The relationships among dose, effectiveness, and side effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):234S-64S.
16. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17.
17. Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005;45:1295-301.
18. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial: Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
19. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
20. Curfman GD, Morrissey S, Drazen JM. Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group." N Engl J Med 2000;343:1520-8. N Engl J Med 2005;353:2813-4.
21. Bombardier C, Laine L, Burgos-Vargas, et al. Response to expression of concern regarding VIGOR study. N Engl J Med 2006;354:1196-99.
22. Farkouh ME, Kirshner H, Harrington RA, et al. TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: Randomised controlled trial. Lancet 2004;364:675-84.
23. Schnitzer TJ, Burmester GR, Mysler E, et al.; TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: Randomised controlled trial. Lancet 2004;364:665-74.
24. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet 2004;364:2021-9.
25. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-8.
26. Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: A population-based case-control study. Arch Intern Med 2005;165:978-84.
27. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: Population based nested case-control analysis. BMJ 2005;330:1366-73.
28. Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 2006;113:1950-7.
29. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006;113:2906-13.
30. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study. Lancet 2005;365:475-81.
31. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004;109:2068-73.
32. Thompson AJ, Yeomans ND. COX-2 inhibition versus gastroprotection with dual COX inhibitors: An evidence-based approach. Curr Pharm Des 2003;9:2221-8.
33. Singh G, Triadafilopoulos G. Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage. Int J Clin Pract 2005;59:1210-7.
34. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002;347:2104-10.
35. Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, Gonzalez-Perez A. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004; 109:3000-6.
36. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360:1071-3.
37. Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004;109:1468-71.
38. Tannenbaum H, Bombardier C, Davis P, Russell AS; Third Canadian Consensus Conference Group. An evidence-based approach to prescribing nonsteroidal anti-inflammatory drugs. Third Canadian Consensus Conference. J Rheumat 2006;33:140-57. (Errata in 2006;33:829, 2006;33:440).
39. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328-46.
40. Bennett JS, Daugherty A, Herrington D, Greenland P, Roberts H, Taubert KA. The use of nonsteroidal anti-inflammatory drugs (NSAIDs): A science advisory from the American Heart Association. Circulation 2005;111:1713-6. (Erratum in 2005;111:1717).
41. Olsen NJ. Tailoring arthritis therapy in the wake of the NSAID crisis. N Engl J Med 2005;352:2578-80.